Differential Bio has emerged from stealth mode with €2 million ($2.2 million) in pre-seed funding to address the challenges of scaling bioprocesses, which are often slow and costly. The Munich-based startup aims to revolutionize biomanufacturing by leveraging AI, microbiology, and lab automation.
According to CEO Christian Spier, the platform is built on three core innovations:
These innovations reduce the dependence on expensive physical experiments and provide valuable insights into key factors like biomass growth rates and metabolite production.
A recent project highlighted the platform's capabilities when a client transitioned from animal-based to plant-based growth media, resulting in a fourfold increase in biomass yield and a 16% reduction in production costs. This exemplifies how the platform aids in simultaneous performance enhancement and cost reduction.
Initially, Differential Bio will conduct data generation and optimization for clients using their proprietary strains. Over time, the platform will become available for partners to use independently, allowing them to conduct virtual experiments without sharing sensitive data. The platform is designed to be user-friendly, enabling users to adjust parameters and run simulations without requiring advanced programming skills.
In conclusion, Differential Bio aims to provide vital data for more efficient biomanufacturing processes, with a focus on exploring non-traditional microbial hosts and sustainable feedstock alternatives.